CompletedPhase 2
A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
Key facts
- Who runs it
- Soterios Ltd
- Where
- United Kingdom9 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 158 people enrolled
- Started
- 23 Mar 2022
- Ended
- 1 Apr 2024
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- STS01
- Placebo
- Record updated
- 7 May 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Active alopecia areata (less than 50% SALT score, present for at least 6 months)
- Not currently receiving treatment for hair loss
- Eighteen years of age or more
- Affected skin with normal appearance and no grossly evident epidermal alteration such as scaling or follicular abnormalities
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Phase 2 double-blind, multi-site, placebo-controlled, parallel-group design to assess the efficacy, safety and dose-response characterisation of STS-01 for the treatment of mild- moderate alopecia areata.
The 5 groups in the trial
- 0.25% DoseTreatment being tested
Once daily, STS-01 topical cream applied to affected area of the head
Treatment: STS01
- 0.5% DoseTreatment being tested
Once daily, STS-01 topical cream applied to affected area of the head
Treatment: STS01
- 1% DoseTreatment being tested
Once daily, STS-01 topical cream applied to affected area of the head
Treatment: STS01
- 2% DoseTreatment being tested
Once daily, STS-01 topical cream applied to affected area of the head
Treatment: STS01
- PlaceboPlacebo, for comparison
Once daily, topical cream applied to affected area of the head (without API)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2 Double-blind, Multicentre, Placebo Controlled, Parallel Group Design to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
- Record updated
- 7 May 2024